These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34814389)

  • 21. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy.
    Jang JW
    World J Gastroenterol; 2014 Jun; 20(24):7675-85. PubMed ID: 24976705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flavonoids as potential anti-hepatocellular carcinoma agents: recent approaches using HepG2 cell line.
    Xia JF; Gao JJ; Inagaki Y; Kokudo N; Nakata M; Tang W
    Drug Discov Ther; 2013 Feb; 7(1):1-8. PubMed ID: 23524937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Taiwan consensus statement on the management of chronic hepatitis B.
    Chien RN; Kao JH; Peng CY; Chen CH; Liu CJ; Huang YH; Hu TH; Yang HI; Lu SN; Ni YH; Chuang WL; Lee CM; Wu JC; Chen PJ; Liaw YF
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):7-38. PubMed ID: 30527436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does anti-HBV therapy benefit the prognosis of HBV-related hepatocellular carcinoma following hepatectomy?
    Yu LH; Li N; Shi J; Guo WX; Wu MC; Cheng SQ
    Ann Surg Oncol; 2014 Mar; 21(3):1010-5. PubMed ID: 24121884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents].
    Liu X; Gao YH; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):944-947. PubMed ID: 29325299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.
    Zhang JY; Dai M; Wang X; Lu WQ; Li DS; Zhang MX; Wang KJ; Dai LP; Han SG; Zhou YF; Zhuang H
    Int J Epidemiol; 1998 Aug; 27(4):574-8. PubMed ID: 9758109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HBV plus HCV, HCV plus HIV, HBV plus HIV.
    Park JS; Saraf N; Dieterich DT
    Curr Gastroenterol Rep; 2006 Feb; 8(1):67-74. PubMed ID: 16510037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?
    Lok AS
    J Gastroenterol Hepatol; 2011 Feb; 26(2):221-7. PubMed ID: 21070361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.
    Wang CC; Tseng KC; Tzeng IS; Kao JH
    J Formos Med Assoc; 2021 Mar; 120(3):965-973. PubMed ID: 33129621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
    Liu CJ
    J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development.
    Hu J; Liu K; Luo J
    Cancer Treat Res; 2019; 177():231-250. PubMed ID: 30523627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.
    Zhu F; Li X
    J Formos Med Assoc; 2021 Apr; 120(4):1160. PubMed ID: 33293200
    [No Abstract]   [Full Text] [Related]  

  • 37. [Strategies of primary prevention of liver cancer in China: Expert Consensus (2018)].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):550-557. PubMed ID: 30060366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection.
    Di Bisceglie AM; Simpson LH; Lotze MT; Hoofnagle JH
    J Clin Gastroenterol; 1994 Oct; 19(3):222-6. PubMed ID: 7528758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma.
    Wei Q; Xu X; Ling Q; Zhou B; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2013 Jun; 12(3):251-5. PubMed ID: 23742769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis.
    Miao RY; Zhao HT; Yang HY; Mao YL; Lu X; Zhao Y; Liu CN; Zhong SX; Sang XT; Huang JF
    World J Gastroenterol; 2010 Jun; 16(23):2931-42. PubMed ID: 20556841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.